The synthetic cathinone 3,4-methylenedioxypyrovalerone increases impulsive action in rats.


Journal

Behavioural pharmacology
ISSN: 1473-5849
Titre abrégé: Behav Pharmacol
Pays: England
ID NLM: 9013016

Informations de publication

Date de publication:
06 2020
Historique:
pubmed: 27 2 2020
medline: 30 1 2021
entrez: 27 2 2020
Statut: ppublish

Résumé

A previous study from our laboratory has shown that the selective catecholamine reuptake inhibitor 3,4-methylenedioxypyrovalerone (MDPV) persistently alters impulsive choice as measured by delay discounting. To further understand the proimpulsive effects of MDPV, we examined its capacity to modulate a different impulsive measure - impulsive action - using a differential reinforcement of low rates of responding task with an inter-response time of 20 s. Three groups of male, Sprague-Dawley rats (n = 6) were first tested in daily sessions to understand the acute effects of cocaine (1.0-30.0 mg/kg), MDPV (0.1-3.0 mg/kg), or saline (1.0 ml/kg) on impulsive action. Both cocaine and MDPV increased impulsive action, most notably by decreasing timing error responses and response efficiency, but MDPV was more effective than cocaine. Additionally, MDPV suppressed operant responding in two of six animals at the highest dose tested. Next, the same animals received 10 postsession injections, once every other day, of either 30.0 mg/kg cocaine, 3.0 mg/kg MDPV, or 1.0 ml/kg saline based on their treatment group. An acute dose-effect redetermination was completed following the repeated administration studies, and once again MDPV and cocaine demonstrated proimpulsive effects. Interestingly, timing error responses were decreased in both MDPV and cocaine groups after an acute saline injection, potentially indicating persistent impulsive changes following the repeated administration phase of the experiment. These studies indicate that MDPV increases impulsive action acutely and that this increase may be potentiated following a series of repeated administrations.

Identifiants

pubmed: 32101987
doi: 10.1097/FBP.0000000000000548
pii: 00008877-202006000-00001
pmc: PMC9356379
mid: NIHMS1826552
doi:

Substances chimiques

Benzodioxoles 0
Pyrrolidines 0
Cocaine I5Y540LHVR
Synthetic Cathinone 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

309-321

Subventions

Organisme : NCRR NIH HHS
ID : UL1 RR029884
Pays : United States
Organisme : NIGMS NIH HHS
ID : P30 GM110702
Pays : United States
Organisme : NINDS NIH HHS
ID : R21 NS100512
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA022981
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA039195
Pays : United States
Organisme : NIDA NIH HHS
ID : R21 DA040907
Pays : United States

Références

Behav Pharmacol. 2017 Aug;28(5):394-400
pubmed: 28598863
Behav Pharmacol. 2009 Sep;20(5-6):400-5
pubmed: 19675455
Exp Clin Psychopharmacol. 2003 Feb;11(1):18-25
pubmed: 12622340
J Forensic Sci. 2013 Nov;58(6):1558-62
pubmed: 23919452
Ann N Y Acad Sci. 2002 Jun;965:172-9
pubmed: 12105093
Transl Psychiatry. 2012 Oct 23;2:e175
pubmed: 23092979
Drug Alcohol Depend. 2016 Oct 01;167:121-7
pubmed: 27520883
Behav Brain Res. 2012 Apr 21;230(1):21-33
pubmed: 22326372
J Anal Toxicol. 2014 Jun;38(5):233-41
pubmed: 24668489
Clin Psychol Rev. 2014 Nov;34(7):551-62
pubmed: 25261740
Psychopharmacology (Berl). 1997 Oct;133(3):207-13
pubmed: 9361325
Psychopharmacology (Berl). 1999 Jun;144(4):389-97
pubmed: 10435412
Behav Neurosci. 2014 Aug;128(4):419-29
pubmed: 24841739
Pharmacol Biochem Behav. 2006 Sep;85(1):114-22
pubmed: 16920182
Drug Alcohol Depend. 2008 Jan 1;92(1-3):69-78
pubmed: 17997051
Psychopharmacology (Berl). 1982;77(1):43-52
pubmed: 6812118
Behav Pharmacol. 2019 Oct;30(7):555-565
pubmed: 31211703
Neuropsychopharmacology. 2017 May;42(6):1182-1191
pubmed: 27976680
Neuropharmacology. 2019 Jan;144:271-281
pubmed: 30321610
J Pharmacol Exp Ther. 1976 Sep;198(3):635-47
pubmed: 978464
J Med Toxicol. 2012 Mar;8(1):69-75
pubmed: 22271565
J Pharmacol Exp Ther. 1983 Jan;224(1):80-8
pubmed: 6848751
Psychopharmacology (Berl). 2016 May;233(10):1981-90
pubmed: 26319160
Cereb Cortex. 2013 Jul;23(7):1509-16
pubmed: 22645252
Eur J Pharmacol. 1992 Mar 3;212(2-3):299-300
pubmed: 1601072
J Pharmacol Exp Ther. 2017 Apr;361(1):181-189
pubmed: 28179474
Psychopharmacology (Berl). 2015 Jul;232(14):2455-62
pubmed: 25724278
J Drug Alcohol Res. 2016 May;5:
pubmed: 27284493
Neurotoxicol Teratol. 2012 Mar;34(2):263-73
pubmed: 22311110
Brain Res Bull. 2016 Sep;126(Pt 1):111-126
pubmed: 27142261
Psychopharmacology (Berl). 2019 Mar;236(3):925-938
pubmed: 30284596
Neuropharmacology. 2018 May 15;134(Pt A):22-27
pubmed: 29042316
Clin Toxicol (Phila). 2011 Jul;49(6):499-505
pubmed: 21824061
Neuropharmacology. 2018 May 15;134(Pt A):65-72
pubmed: 29030166
Addict Behav. 2016 Jul;58:104-9
pubmed: 26922157
Br J Pharmacol. 2014 Oct;171(20):4729-66
pubmed: 24866553
Br J Pharmacol. 2013 Jan;168(2):458-70
pubmed: 22897747
Int J Neuropsychopharmacol. 2012 Nov;15(10):1473-87
pubmed: 22094071
Front Psychol. 2015 Dec 18;6:1910
pubmed: 26733906
Curr Top Behav Neurosci. 2017;32:93-117
pubmed: 27830575
Neuropharmacology. 2014 Dec;87:59-65
pubmed: 24456744
Am J Case Rep. 2013 Jul 31;14:288-91
pubmed: 23919103
Invest Clin. 1993;34(4):181-92
pubmed: 7516188
Exp Aging Res. 1983 Spring;9(1):23-5
pubmed: 6861835
Addict Behav. 2014 Nov;39(11):1632-1639
pubmed: 24864028
Behav Processes. 1995 Jul;34(2):153-60
pubmed: 24897515
Br J Pharmacol. 2011 Oct;164(4):1301-21
pubmed: 21410459
J Pharmacol Exp Ther. 2016 Mar;356(3):615-23
pubmed: 26769917
Eur J Pharmacol. 1990 Sep 4;186(1):1-8
pubmed: 2282931
JAMA Psychiatry. 2013 Aug;70(8):857-68
pubmed: 23803700
J Pharmacol Exp Ther. 2005 May;313(2):848-54
pubmed: 15677348
Pharmacol Biochem Behav. 1978 Sep;9(3):327-37
pubmed: 714982
Psychopharmacology (Berl). 1991;103(1):121-8
pubmed: 2006238
Behav Pharmacol. 2011 Jun;22(3):248-61
pubmed: 21499079
Neuropsychopharmacology. 2018 Nov;43(12):2399-2407
pubmed: 30305739
Clin Neurophysiol. 2013 Jun;124(6):1122-31
pubmed: 23332777
J Pharmacol Exp Ther. 2003 Oct;307(1):356-66
pubmed: 12954808
Ann Emerg Med. 2012 Jul;60(1):103-5
pubmed: 22387085
Pharmacol Biochem Behav. 1990 Mar;35(3):595-600
pubmed: 2339152
Front Psychiatry. 2018 Feb 13;9:26
pubmed: 29491842
Neurotoxicology. 2012 Oct;33(5):1305-13
pubmed: 22922498
Psychopharmacology (Berl). 1999 Oct;146(4):432-9
pubmed: 10550493
Behav Brain Res. 2003 Dec 17;147(1-2):135-47
pubmed: 14659579
Neuropharmacology. 2018 Jul 15;137:178-193
pubmed: 29729891
Dev Psychol. 2008 Nov;44(6):1764-78
pubmed: 18999337

Auteurs

William S Hyatt (WS)

Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas.

Caitlin E Hirsh (CE)

Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas.

Lauren N Russell (LN)

Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas.

Neha M Chitre (NM)

Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, Georgia.

Kevin S Murnane (KS)

Department of Pharmaceutical Sciences, College of Pharmacy, Mercer University, Atlanta, Georgia.

Kenner C Rice (KC)

Drug Design and Synthesis Section, Intramural Research Program, National Institute of Drug Abuse, IRP, NIH, Baltimore, Maryland, USA.

William E Fantegrossi (WE)

Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH